Levomilnacipran
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Levomilnacipran
Levomilnacipran: Benign paroxysmal torticollis of infancy
One-Sentence Summary
Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) originally used to treat depression and anxiety-related conditions. The TxGNN model predicts it may be effective for benign paroxysmal torticollis of infancy, but no clinical trials and no publications currently support this prediction. The result is a computational signal only and should be treated as a hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Benign paroxysmal torticollis of infancy |
| TxGNN Prediction Score | 0.9953 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, levomilnacipran is an SNRI, and its efficacy in major depressive disorder is established in the literature, with approval in adults.
The link to the predicted indication is weak. Benign paroxysmal torticollis of infancy is a paediatric disorder often associated with channelopathy (commonly CACNA1A variants). It is not an obvious target for serotonin and norepinephrine reuptake inhibition. Levomilnacipran is also approved only for adults. The very high score (rank 8011 in the model’s ranking) reflects a computational prediction, not a demonstrated mechanistic or clinical rationale.
Other predictions from the same model
For context, the other top-ranked predictions are listed below. None has clinical trial support.
| Rank | Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|---|
| 2 | Agoraphobia | 0.9953 | L5 | Plausible, since SNRIs and SSRIs are used in related anxiety and panic disorders, but no supporting studies were found |
| 6 | Neurotic disorder | 0.9919 | L5 | Outdated umbrella category; too vague to be actionable |
Clinical Trial Evidence
Currently no related clinical trials registered for benign paroxysmal torticollis of infancy.
Literature Evidence
Currently no related literature available for benign paroxysmal torticollis of infancy.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 121730 | Levomil 20 Capsule ER | Strip of 10 extended-release capsules | Not stated |
| 122014 | Levomil 40 Capsule ER | Strip of 10 extended-release capsules | Not stated |
| 127120 | Levomil 80mg Tablet | Strip of 10 tablets | Not stated |
All three are single-ingredient products from Intas Pharmaceuticals Ltd, and all are currently valid.
Safety Considerations
- Drug Interactions: 135 interactions were identified in the interaction database. Examples of those rated Major: bupropion, lorcaserin, clarithromycin, diethylpropion, dolasetron, palonosetron, phentermine, dexfenfluramine and fenfluramine. Examples rated Moderate: isometheptene, epinephrine, morphine, acetylsalicylic acid, ephedrine, and several bowel-preparation products (picosulfuric acid, sodium sulfate, polyethylene glycol with electrolytes).
- Disease-related contraindications (knowledge graph): angle-closure glaucoma.
- Population note: Levomilnacipran is approved only for adults, which is a particular concern for a paediatric (infant) predicted indication.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no clinical trials or publications for this indication. The disease is a paediatric channelopathy-related condition with no clear link to SNRI pharmacology, and the drug is approved only for adults. Evidence is model prediction only (L5).
To proceed, the following is needed:
- Mechanism of action data to assess any plausible biological link
- Package insert warnings and contraindications from the Indian regulator, since these are currently missing and block safety screening
- Preclinical or mechanistic evidence supporting use in this disorder
- A paediatric safety assessment, given the adult-only approval
- Consideration of more plausible candidates from the same model run, such as dysthymic disorder or agoraphobia, which are better aligned with the drug’s known pharmacology
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.